Compare Natera Inc. Common Stock (NTRA) vs Ondas Inc. Common Stock (ONDS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Ondas Inc. Common Stock — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Ondas Inc. Common Stock trades at $6.03 (market cap $3.90B). The key difference: Natera Inc. Common Stock is far larger — about 14.6× Ondas Inc. Common Stock's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Ondas Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Ondas Inc. Common Stock for 2 Days on average.
| NTRA | ONDS | |
|---|---|---|
Market Cap | $57.03B | $3.90B |
Volume | 1,131,157 | 70,281,019 |
Sector | Health | Technology |
52-Week High | $425.64 | $14.01 |
52-Week Low | $179.42 | $5.25 |
Typical Hold Time | 0 Days | 2 Days |
Enterprise Value | $56.18B | $2.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
ONDS trades at $6.71, up 0.6% on the day, amid mixed technical signals with a bearish moving average trend but oversold RSI levels. The company reported a net loss of $132.02M for 2025 but shows a projected turnaround to $168M net profit for 2026. Recent developments include a strategic AI venture with Palantir and over $270M in new defense orders, boosting revenue visibility. Analyst sentiment is unanimously bullish with a consensus price target of $18.50.
The outlook for ONDS hinges on executing its growth strategy and achieving profitability targets. Investment opportunity lies in its expanding defense contracts and AI initiatives, but risks include persistent cash burn, high valuation multiples, and sector volatility. The stock presents a high-risk, high-reward profile dependent on successful operational execution and market adoption of its autonomous defense technologies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Ondas Inc. Common Stock
Ondas provides autonomous systems and private wireless solutions through its Ondas Autonomous Systems, Ondas Capital, and Ondas Networks business units. Its technologies combine aerial intelligence and next-generation connectivity for essential industries.
Read more on ONDS →
